logo-loader
viewDyadic International Inc

Dyadic International posts higher revenue from R&D, new sublicensing collaborations

Dyadic International Inc (NASDAQ:DYAI) Chief Accounting Officer Ping Rawson says the Florida-based biotech reported a 119% increase in first-quarter research and development revenue compared to the same period a year ago.

Chief Scientific Officer Ronen Tchelet explained the value of its recently formed, exciting sub-licensing agreements with both Alphazyme and Serum Institute of India.

Quick facts: Dyadic International Inc

Price: 6.07 USD

NASDAQ:DYAI
Market: NASDAQ
Market Cap: $166.74 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Dyadic International Inc named herein, including the promotion by the Company of Dyadic International Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Dyadic paves the way for patients to gain access to low-cost...

Dyadic (NASDAQ) President and CEO Mark Emalfarb joined Steve Darling from Proactive Vancouver with news the company continues to very busy even with the COVID-19 crisis. Emalfarb discussing what the company is doing with other partners to help battle the virus.  Emalfarb also telling...

on 1/4/20

2 min read